While there is interest in applying local therapies to OM and OP breast cancer, the current randomized data does not back the routine use of surgery or SBRT, particularly when considering the potential for treatment-related toxicities. Future research should refine patient selection through advanced imaging and possibly explore these therapies specifically in patients with hormone receptor-positive or HER2-positive disease.
Keyphrases
- current status
- minimally invasive
- double blind
- radiation therapy
- high resolution
- open label
- coronary artery bypass
- case report
- electronic health record
- clinical practice
- placebo controlled
- clinical trial
- phase iii
- big data
- phase ii
- risk assessment
- human health
- atrial fibrillation
- data analysis
- replacement therapy
- deep learning